BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day
Rhea-AI Summary
BrainsWay (NASDAQ: BWAY) announced management will hold one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York. Investors or analysts should contact their Citi representative to request a meeting.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Minority-stake investment | Positive | -7.5% | Announced staged minority equity investment in BrainStim Health with milestone tranches. |
| Feb 18 | Coverage expansion | Positive | +4.3% | Evernorth Behavioral Health removed prior authorization for TMS coverage. |
| Feb 17 | ADS ratio change | Neutral | +8.6% | Changed ADS-to-ordinary share ratio to 1-to-1, a 2-for-1 ADS split. |
| Jan 21 | Coverage policy draft | Positive | +4.7% | Highmark draft policy expanding coverage for accelerated Deep TMS protocol. |
| Jan 12 | FDA device approval | Positive | +4.7% | FDA PMA approval for Proliv™Rx at-home neuromodulation system for MDD. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent operational and coverage wins have generally seen positive price reactions, with one notable selloff following an investment announcement.
Over the past months, BrainsWay reported several milestones. On Jan 12, 2026, it highlighted FDA Premarket Approval for the Proliv™Rx neuromodulation system, which saw a 4.67% gain. Payer coverage updates from Highmark and Evernorth in January and February produced reactions of 4.74% and 4.29%. A 2-for-1 ADS forward split on Mar 3, 2026 drove an 8.61% move. The minority-stake BrainStim Health investment on Feb 19, 2026 coincided with a -7.45% decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY.
Please contact your Citi representative to request a meeting at the conference.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
